EQRx's pricing reform model on life support as execs shed PD-L1 plans in US for lung cancer
EQRx placed a substantial bet it could shake up the US healthcare system, promising to bring a swath of drugs to market that was similar to products from other Big Pharmas but priced substantially lower. Its first effort has just fallen flat — and it appears it’s backtracking on at least some of its pricing promises.
In a third quarter update early Thursday morning, EQRx bluntly announced that its anti-PD-L1 drug, dubbed sugemalimab, is no longer commercially viable in lung cancer, and execs will instead prioritize two other clinical programs. EQRx said the path to market was cut off after FDA feedback suggested sugemalimab would need to clear a substantially higher threshold in a Phase III study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.